Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome

by Parc Científic de Barcelona

Avizorex Pharma –an ophthalmology biotech company with offices at Barcelona Science Park (PCB)– announcesthe submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority, re...

Read more

Avizorex Pharma submits clinical trial application for its lead compound AVX-012 for dry eye syndrome

by Inveready

AVX-012, a Small Molecule with a novel mechanism of action, to be investigated as a potential new treatment for mild to moderate Dry Eye Syndrome.

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream